Physician profile
Eric Roger Nicely
NPI 1043210164
$2,012.21
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,973 · 2020: $38.94.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,289.19 | 2019 | |
| Amgen INC. | $241.61 | 2019 | |
| Endo Pharmaceuticals INC. | $134.81 | 2019 | |
| Astellas Pharma US INC | $83.92 | 2019 | |
| Rochester Medical Corporation | $59.10 | 2019-2020 | |
| Pfizer INC. | $57.53 | 2019-2020 | |
| Boston Scientific Corporation | $52.14 | 2019 | |
| Abbvie INC. | $25.23 | 2019 | |
| Zyla Life Sciences, INC. | $23.57 | 2019 | |
| Ferring Pharmaceuticals INC. | $19.42 | 2019 | |
| Olympus America INC. | $13.77 | 2019 | |
| Avadel Specialty Pharmaceuticals, LLC | $11.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Nicely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.